KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Depreciation & Amortization (CF): 2009-2025

Historic Depreciation & Amortization (CF) for Rigel Pharmaceuticals (RIGL) over the last 15 years, with Sep 2025 value amounting to $603,000.

  • Rigel Pharmaceuticals' Depreciation & Amortization (CF) fell 1.31% to $603,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year increase of 26.13%. This contributed to the annual value of $2.2 million for FY2024, which is 79.97% up from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Depreciation & Amortization (CF) stood at $603,000, which was down 0.66% from $607,000 recorded in Q2 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Depreciation & Amortization (CF) peaked at $613,000 during Q2 2024, and registered a low of $237,000 during Q1 2022.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $603,000 (2025), whereas its average is $480,000.
  • Per our database at Business Quant, Rigel Pharmaceuticals' Depreciation & Amortization (CF) declined by 29.70% in 2022 and then skyrocketed by 109.25% in 2024.
  • Quarterly analysis of 5 years shows Rigel Pharmaceuticals' Depreciation & Amortization (CF) stood at $404,000 in 2021, then decreased by 29.70% to $284,000 in 2022, then increased by 3.17% to $293,000 in 2023, then surged by 106.14% to $604,000 in 2024, then dropped by 1.31% to $603,000 in 2025.
  • Its last three reported values are $603,000 in Q3 2025, $607,000 for Q2 2025, and $604,000 during Q1 2025.